KindlyMD, Inc. (NASDAQ:NAKA) Short Interest Update

KindlyMD, Inc. (NASDAQ:NAKA) was the recipient of a significant decline in short interest in the month of May. As of May 29th, there was short interest totaling 986,003 shares, a decline of 96.8% from the May 14th total of 30,827,459 shares. Currently, 7.5% of the shares of the stock are sold short. Based on an average trading volume of 564,906 shares, the short-interest ratio is presently 1.7 days.

Analyst Upgrades and Downgrades

Several equities analysts have commented on NAKA shares. Wall Street Zen upgraded shares of KindlyMD to a “sell” rating in a report on Saturday, May 23rd. TD Cowen initiated coverage on KindlyMD in a report on Friday, April 10th. They set a “buy” rating and a $40.00 price target for the company. Weiss Ratings upgraded KindlyMD from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. B. Riley Financial dropped their price target on shares of KindlyMD from $40.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, February 23rd. Finally, Maxim Group lowered their price target on KindlyMD from $60.00 to $30.00 and set a “buy” rating for the company in a research note on Monday, April 6th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $30.00.

KindlyMD Stock Performance

KindlyMD stock traded up $0.39 during midday trading on Thursday, reaching $4.47. The stock had a trading volume of 659,398 shares, compared to its average volume of 194,122. KindlyMD has a 1-year low of $4.05 and a 1-year high of $764.00. The firm’s fifty day simple moving average is $7.38 and its 200-day simple moving average is $11.83. The stock has a market capitalization of $77.78 million, a P/E ratio of -0.10 and a beta of 15.84.

KindlyMD (NASDAQ:NAKA) last announced its earnings results on Wednesday, May 13th. The company reported ($0.38) EPS for the quarter. KindlyMD had a negative return on equity of 81.32% and a negative net margin of 7,397.12%.The business had revenue of $2.68 million for the quarter. On average, sell-side analysts anticipate that KindlyMD will post -16.8 earnings per share for the current fiscal year.

Insider Transactions at KindlyMD

In other news, CEO David F. Bailey bought 104,833 shares of the stock in a transaction that occurred on Wednesday, May 27th. The shares were purchased at an average cost of $4.84 per share, with a total value of $507,391.72. Following the completion of the acquisition, the chief executive officer directly owned 3,120,361 shares in the company, valued at approximately $15,102,547.24. The trade was a 3.48% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders bought 191,448 shares of company stock worth $992,908 over the last quarter. 24.49% of the stock is owned by insiders.

Institutional Trading of KindlyMD

A number of hedge funds have recently modified their holdings of the stock. J. Derek Lewis & Associates Inc. acquired a new stake in KindlyMD in the 4th quarter worth about $167,000. Virtu Financial LLC acquired a new stake in KindlyMD in the 4th quarter worth about $151,000. Invesco Ltd. acquired a new stake in KindlyMD in the 4th quarter worth about $211,000. NewEdge Advisors LLC acquired a new stake in KindlyMD in the 4th quarter worth about $316,000. Finally, Saba Capital Management L.P. acquired a new stake in KindlyMD in the 4th quarter worth about $1,399,000.

KindlyMD Company Profile

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.